RECEIVED CENTRAL FAX CENTER

SEP 1 3 2005

FACSIMILE COVER SHEET

LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK Tower
1101 Market Street
Philadelphia, PA 19107-2950

Phone No.: (215) 923-4466 Facsimile No.: (215) 923-2189

PLEASE DELIVER THE FACSIMILE TRANSMITTED HEREWITH TO:

Name: U.S. Patent and Trademark Office
From: Jonathan M. Dermott, Ph.D.
Re: U.S. Application No. 10/006,177 C'ytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment, and Diagnosis of Cancer S&L Docket No.: P30,631 USA
A total of 9 page(s), including this cover sheet, will be transmitted.
Confirmation copy sent: Yes XX No
Name of Operator: Barbara G. Makariou
Date Sent: September 13, 2005
Facsimile No.: 1-571-273-8300
REMARKS: ******OFFICIAL COMMUNICATION*****

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF YOU HAVE RECEIVED THIS MESSAGE IN ERROR PLEASE NOTIFY US BY TELEPHONE IMMEDIATELY. TO DO SO, YOU MAY CALL US COLLECT.

RECEIVED CENTRAL FAX CENTER

LAW OFFICES OF

SYNNESTVEDT & LECHNER LLP

SEP 1 3 2005

2600 ARAMARK TOWER
HIGH MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466

FACSIMILE (21A) 963-2169 L-MAIL Bynnlech@synnlech.com www.synnlech.com

OFFICIAL COMMUNICATION

September 13, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Venky Ramakrishna, Mark M. Ross, and Ramila Philip
Application No. 10/006,177
Filed December 4, 2001

Examiner: M. Yu, Ph.D. Group Art Unit: 1642 Confirmation No. 2918

CYTOTOXIC T-LYMPHOCYTE-INDUCING IMMUNOGENS FOR PREVENTION, TREATMENT, AND DIAGNOSIS OF CANCER

(Atty. Docket No. P30,631 USA)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office to facsimile number 571-273-8300 on September 13, 2005.

Barbara G. Makariou

AMENDMENT UNDER 37 C.F.R. §1.111

Sir:

In response to the Examiner's interview, dated September 12, 2005, the following amendments and remarks are respectfully submitted.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.